Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

3articles mentioning institutions

5institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: BOREAS ×

BOREAS

This institution is selected. Its supporting articles are shown below.

Articles mentioning BOREAS

3 articles · page 1 of 1

M13 Antibiotic and systemic corticosteroid use in patients with chronic obstructive pulmonary disease and type 2 inflammation receiving dupilumab

thoraxjnl · abstract · 2025-11-02 · 2 matching annotations

81.8%

BOREAS NOTUS dupilumab chronic obstructive pulmonary disease COPD triple therapy

…CS and antibiotic use in patients from BOREAS and NOTUS.Methods BOREAS ( NCT03930732) and NOTUS (NCT04456673), phase 3, randomized, pl…

M14 Association between early lung function improvement with dupilumab and sustained clinical outcomes in patients with chronic obstructive pulmonary disease: a clinical perspective

thoraxjnl · abstract · 2025-11-02 · 2 matching annotations

78.3%

NOTUS BOREAS dupilumab COPD chronic obstructive pulmonary disease type 2 inflammation

…, key and central drivers of type 2 inflammation. In BOREAS and NOTUS, dupilumab reduced exacerbations and improved lung function in …

S174 Reduction of exacerbations according to type 2 inflammatory biomarkers with dupilumab treatment in patients with chronic obstructive pulmonary disease

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

78.3%

BOREAS NCT03930732 NOTUS dupilumab chronic obstructive pulmonary disease COPD type 2 inflammation triple inhalation therapy

…Purpose In BOREAS and NOTUS, add-on dupilumab reduced moderate-or-severe exacerba…